EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

cyclovirobuxine D
bebuxine

Supplier Sponsors

CAS Number: 860-79-7Picture of molecule3D/inchi
FDA UNII: 51GY352868
XlogP3-AA:5.90 (est)
Molecular Weight:402.66582000
Formula:C26 H46 N2 O
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:pharmaceuticals / chemical synthisis
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Boiling Point: 495.67 °C. @ 760.00 mm Hg (est)
Flash Point: 93.00 °F. TCC ( 34.10 °C. ) (est)
logP (o/w): 4.635 (est)
Soluble in:
 water, 0.3869 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
Alfa Biotechnology
For experimental / research use only.
Cyclovirobuxine D 98%
BOC Sciences
For experimental / research use only.
Cyclovirobuxine D >98%
Odor: characteristic
Use: Cyclovirobuxine D is an active compound extracted from Buxus microphylla, which has been used for treating acute myocardial ischemia.
Changsha Organic Herb
Cyclovirobuxine D
Santa Cruz Biotechnology
For experimental / research use only.
Cyclovirobuxine D ≥98%
 
Safety Information:
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intraperitoneal-mouse LD50 9200 ug/kg
Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. Vol. 3, Pg. 101, 1982.

intravenous-mouse LD50 8900 ug/kg
Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. Vol. 3, Pg. 101, 1982.

oral-mouse LD50 293 mg/kg
Zhongguo Yaoli Xuebao. Acta Pharmacologica Sinica. Chinese Journal of Pharmacology. Vol. 3, Pg. 101, 1982.

Dermal Toxicity:
Not determined
Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
pharmaceuticals / chemical synthisis
 
 
Safety References:
EPI System: View
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :196993
National Institute of Allergy and Infectious Diseases:Data
Chemidplus:0000860797
 
References:
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):196993
Pubchem (sid):135174298
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
HMDB (The Human Metabolome Database):Search
VCF-Online:VCF Volatile Compounds in Food
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 buxus microphylla
Search Trop Picture
 
Synonyms:
 bebuxine
9,19-cyclo-5-alpha,9-beta-pregnan-16-alpha-ol, 4,4,14-trimethyl-3-beta,20-alpha-bis(methylamino)-
9,19-cyclopregnan-16-ol, 4,4,14-trimethyl-3,20-bis(methylamino)-, (3beta,5alpha,16alpha,20S)-
 cyclovirobuxin D
 

Articles:

PubMed:Cyclovirobuxine D Induces Autophagy-Associated Cell Death via the Akt/mTOR Pathway in MCF-7 Human Breast Cancer Cells.
PubMed:Experimental and theoretical investigation on the interaction between cyclovirobuxine D and human serum albumin.
PubMed:Influence of cyclovirobuxine D on intracellular [Ca(2+)] regulation and the expression of the calcium cycling proteins in rat myocytes.
PubMed:[Effects of CVB-D on hemodynamic in anaesthetized dogs in vivo].
PubMed:Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction.
PubMed:Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells.
PubMed:[Studies of in vitro releasing properties on cyclovirobuxine D matrix-type patch].
PubMed:Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis.
PubMed:Short and efficient approach towards buxozine-C, an alkaloid from Buxus sempervirens.
PubMed:[Determination of cyclovirobuxine-D in huangyangning tablets by RP-HPLC with gradient elution].
PubMed:Sensitive HPLC-APCI-MS method for the determination of cyclovirobuxine D in human plasma.
PubMed:High performance liquid chromatography - tandem mass spectrometric determination of cyclovirobuxine D in human plasma.
PubMed:[Structural modification of cyclovirobuxine D and their inhibition activity on lipid peroxidation].
PubMed:[Prodrug structural modifications of cyclovirobuxine D and their biological activity].
PubMed:Regulation of Ca2+ movements by cyclovirobuxine D in ECV304 endothelial cells.
PubMed:[Electrophysiologic study of the biphasic effects of cyclovirobuxine D on arrhythmias].
PubMed:[Effects of cyclovirobuxine D on intracellular Ca2+ and L-type Ca2+ current in rat ventricular cardiomyocytes].
PubMed:[Structural modification and bioactivity of cyclovirobuxine D].
PubMed:[Determination of cyclovirobuxine D by RP-HPLC with precolumn fluorescence derivatization].
PubMed:Coronary effects of cyclovirobuxine D in anesthetized pigs and in isolated porcine coronary arteries.
PubMed:Hemodynamic effects of the intravenous administration of cyclovirobuxine D [correction of cyclorirobuxine D] in anesthetized pigs.
PubMed:[Anti-atrial fibrillation effects of cyclovirobuxine-D and its electrophysiological mechanism studied on guinea pig atria].
PubMed:Protective effect of cycloprotobuxine-A against cardiac arrhythmias induced by ouabain.
PubMed:[Congestive heart failure treated by a combination of cyclovirobuxine D with digoxin].
PubMed:Anti-arrhythmic action of cycloprotobuxine-A.
PubMed:The beneficial effects of cyclovirobuxine D (CVBD) in coronary heart disease. A double blind analysis of 110 cases.
PubMed:[Double blind study of the therapeutic effect of cyclovirobuxine D No. 1 on the left ventricular function in coronary heart disease].
PubMed:[Clinical observation of 546 cases of coronary heart disease treated with cyclovirobuxine D].
PubMed:[Some cardiovascular effects of cyclovirobuxine-D (author's transl)].
PubMed:[Experimental analysis of the anti-arrhythmic and arrhythmia-inducing actions of cyclovirobuxine D (author's transl)].
 
Notes:
active priciple of buxus microphylla var. sinica; has anti-arrhythmic & arrhythmia-inducing actions.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy